Guillain-Barre Syndrome Diagnostics Market Size, Share & Trends Report By Test (Lumbar Puncture, Electromyography), By End-use (Hospitals And Clinics, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global guillain-barre syndrome diagnostics market size was estimated at USD 144.5 million in 2024 and is projected to grow at a CAGR of 2.8% from 2025 to 2030. This upward trend is driven by several key factors, including the increasing prevalence of Guillain-Barre syndrome (GBS), advancements in diagnostic techniques, and heightened awareness of the condition among healthcare professionals and the general public. The rising incidence of GBS, particularly in regions with high rates of infectious diseases, underscores the need for effective diagnostic tools, thereby propelling market expansion.

Guillain-Barré syndrome can affect individuals of all ages, though it is most frequently diagnosed in people between 30 and 50 years old. As a rare neurological disorder, it impacts approximately 100,000 individuals worldwide each year. In the U.S., estimates from the CDC indicate that between 3,000 and 6,000 new cases are reported annually. Recently, in January 2025, at least 67 cases of GBS were identified in Pune, Maharashtra, prompting concerns among health officials. Authorities are closely monitoring the situation and investigating the potential causes of this surge. Regions with frequent infectious disease outbreaks tend to report higher incidence rates of GBS, driving demand for more effective diagnostic tools and treatment options.

A key factor fueling the growth of the market is the expanding geriatric population. According to the World Health Organization (WHO), by 2030, one in six people globally is expected to be aged 60 or older, with the number of individuals in this age group increasing from 1 billion in 2020 to 1.4 billion by 2050. This demographic shift is crucial, as older adults are more vulnerable to a range of health conditions, including autoimmune disorders like GBS. As a result, the need for improved diagnostic capabilities is growing to ensure early detection and effective management of the condition.

The COVID-19 pandemic has also played a role in highlighting the importance of timely diagnosis and treatment of GBS. Studies have indicated a correlation between COVID-19 infections and the onset of GBS, with reports suggesting that a notable percentage of GBS patients had preceding COVID-19 infections during the early months of the pandemic. This association has underscored the critical need for effective diagnostic tools, thereby stimulating market growth.

Advancements in diagnostic techniques have further propelled the market growth. Innovations such as nerve conduction studies and electromyography have improved the accuracy and speed of GBS diagnosis, enabling healthcare providers to initiate appropriate treatments promptly. These technological advancements not only enhance patient outcomes but also contribute to the expansion of the diagnostics market by increasing the demand for advanced diagnostic equipment and procedures.

Pipeline for Guillain-Barré Syndrome Diagnostics

Case Studies on GBS Diagnostics

Case Study 1: Classic GBS with Albuminocytologic Dissociation

Summary:

• A 55-year-old male presented with progressive weakness in the legs, areflexia, and mild sensory symptoms.

• CSF analysis revealed elevated protein (120 mg/dL) with normal cell count.

• Nerve conduction studies showed demyelination with prolonged distal latencies.

• Diagnosis: Acute inflammatory demyelinating polyneuropathy (AIDP), the most common subtype of GBS.

Case Study 2: GBS Post-Zika Virus Infection

Summary:

• A 30-year-old male developed GBS after a Zika virus infection.

• CSF analysis showed elevated protein levels.

• Nerve conduction studies revealed demyelination.

• Diagnosis: GBS associated with Zika virus infection.

Market Dynamics

The market is witnessing continuous advancements in diagnostic techniques, including nerve conduction studies, electromyography, and biomarker-based tests. Emerging technologies such as AI-driven diagnostics and rapid molecular assays are enhancing accuracy and early detection. Increased R&D investments are driving innovation, improving patient outcomes, and expanding diagnostic capabilities.

Mergers and acquisitions in the market are increasing as major healthcare and biotechnology firms seek to expand their diagnostic portfolios. Companies are acquiring innovative startups to enhance technological capabilities, streamline research efforts, and strengthen market presence. Strategic collaborations are fostering innovation, accelerating product development, and improving accessibility.

Regulatory frameworks play a crucial role in shaping the GBS diagnostics market. Stringent approval processes for diagnostic tools and compliance with international standards impact product availability. Government policies supporting rare disease research and reimbursement schemes influence market growth, ensuring safety while promoting the adoption of advanced diagnostic solutions globally.

The market is experiencing considerable product expansion, with companies developing advanced diagnostic assays, point-of-care tests, and AI-powered diagnostic tools. Improved biomarker research has led to more precise and faster diagnostic methods. Increasing demand for early detection solutions is driving the introduction of novel products tailored for better disease management.

The market is expanding geographically, with companies focusing on emerging economies where healthcare infrastructure is improving. Increased awareness, growing patient populations, and government initiatives in Asia-Pacific, Latin America, and Africa are driving market penetration. Collaborations with regional healthcare providers are enhancing accessibility to advanced diagnostic solutions.

Test Insights

The test segment of the market includes lumbar puncture, electromyography, nerve conduction studies, and others. The lumbar puncture segment led the market in 2024, accounting for the largest revenue share of 45.1%, and is expected to experience the fastest CAGR of 3.0% during the forecast period, driven by its essential role in confirming GBS diagnosis. Lumbar puncture or spinal tap enables the collection of cerebrospinal fluid (CSF), which is crucial for identifying protein levels and detecting the albuminocytological dissociation characteristic of GBS. This minimally invasive procedure is gaining traction due to improvements in imaging and diagnostic accuracy. Healthcare providers increasingly rely on lumbar puncture as a complementary diagnostic tool alongside nerve conduction studies and electromyography to provide a comprehensive assessment of patients. Rising GBS incidence and greater emphasis on early and precise diagnosis have bolstered demand for lumbar puncture procedures. In addition, technological advancements and improved procedural safety are expected to propel market growth further. As diagnostic protocols evolve, the lumbar puncture segment will continue to play a pivotal role in advancing the overall capabilities of the GBS diagnostics market.

Nerve conduction studies (NCS) diagnostics are experiencing significant market growth within the Guillain-Barré Syndrome (GBS) diagnostics space, driven by increasing incidence rates and the need for early, accurate diagnosis. With GBS being a condition characterized by nerve damage and impaired signal transmission, NCS serves as an indispensable tool for clinicians. These studies assess the integrity and function of peripheral nerves by measuring the speed and amplitude of electrical impulses, thereby providing critical information for distinguishing between demyelinating and axonal variants of GBS. Technological advancements have led to more precise and user-friendly NCS equipment, enhancing diagnostic reliability and efficiency.

End-use Insights

The end-use segment comprises hospitals & clinics and diagnostic laboratories. In 2024, the hospitals & clinics segment led the market, capturing a revenue share of 63.0%, driving significant growth through the integration of advanced diagnostic tools and improved patient management protocols. As primary points of care, these healthcare institutions are increasingly adopting state-of-the-art diagnostic technologies, such as nerve conduction studies and lumbar puncture techniques, to facilitate early and precise GBS detection. The rising incidence of GBS, coupled with growing awareness about its early symptoms, has led hospitals and clinics to invest heavily in sophisticated diagnostic equipment. Furthermore, advancements in medical imaging and laboratory testing have enhanced diagnostic accuracy, resulting in improved patient outcomes.

Diagnostic laboratories are at the forefront of driving growth in the market as they continuously adopt advanced methodologies for precise identification and analysis of the syndrome. These laboratories utilize state-of-the-art equipment, including nerve conduction studies, lumbar puncture, and cerebrospinal fluid analysis, to detect the characteristic markers of GBS. Technological advancements and automation in sample processing have enhanced efficiency and accuracy, leading to quicker diagnosis and better patient outcomes. In addition, increased investment in R&D and heightened awareness of GBS have pushed diagnostic laboratories to integrate innovative diagnostic techniques and expand their testing capabilities. This evolution in laboratory technology and capacity is fueled by the rising demand for early and accurate diagnosis of GBS in clinical settings, thereby propelling market expansion. The robust performance of diagnostic laboratories continues to contribute significantly to the overall growth of the market, establishing them as crucial stakeholders in the healthcare ecosystem.

Regional Insights

North America Guillain-Barre Syndrome diagnostics market had a considerable global market share in 2024. This large share is attributed to the increasing disease awareness, advancements in diagnostic techniques, and higher diagnosis rates. The U.S. and Canada are key contributors, benefiting from well-established healthcare systems and improved diagnostic accessibility. In addition, the expansion of online healthcare services is enhancing access to GBS diagnostic solutions.

U.S. GBS Diagnostics Market Trends

The Guillain-Barre Syndrome diagnostics market in the U.S. dominated the North American region in 2024. The rising prevalence of GBS, linked to autoimmune disorders and infectious diseases, has fueled the demand for advanced diagnostic tools. The Centers for Disease Control and Prevention (CDC) has reported an increasing incidence of GBS, prompting the need for enhanced diagnostic methods, including electromyography (EMG), nerve conduction studies (NCS), and cerebrospinal fluid (CSF) analysis.

Europe GBS Diagnostics Market Trends

The GBS diagnostics market in Europe is expanding due to heightened awareness and improved detection rates. Countries such as the UK, Germany, and France are experiencing increased demand for advanced diagnostic solutions driven by better healthcare infrastructure and early diagnosis initiatives. Public health campaigns are playing a significant role in improving awareness and expanding access to diagnostic tools.

The Guillain-Barre Syndrome diagnostics market in the UK is growing due to increased awareness and a stronger emphasis on early detection. Government initiatives and awareness campaigns are boosting demand for diagnostic tools, with hospital-based laboratories and diagnostic centers playing a central role in early disease identification.

Germany’s Guillain-Barre Syndrome diagnostics market growth is fueled by public health initiatives and widespread recognition of GBS symptoms. The demand for precise diagnostic techniques such as nerve conduction studies, lumbar punctures, and biomarker-based tests is increasing. Awareness of conditions like chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and acute motor axonal neuropathy (AMAN) is also driving the need for accurate diagnostics.

The Guillain-Barre Syndrome diagnostics market in France is expanding due to improved healthcare accessibility and technological advancements in diagnostics. The competitive landscape is strengthening, with both local and international players investing in innovative diagnostic solutions, including rapid molecular tests and advanced imaging techniques.

Asia Pacific GBS Diagnostics Market Trends

Asia Pacific Guillain-Barre Syndrome diagnostics market dominated globally in 2024 with a market share of 41.8%. Factors such as rising disease awareness, improving healthcare infrastructure, and increasing diagnostic rates are driving market expansion. The demand for advanced diagnostic methods, including neurophysiological tests and biomarker-based assays, is rising due to an increasing number of diagnosed cases.

The Japan GBS diagnostics market growth can be attributed to lifestyle changes and growing awareness of GBS, leading to increasing demand for early GBS diagnosis. Hospitals and specialized diagnostic centers are investing in advanced diagnostic techniques such as electrophysiological testing and CSF protein analysis to improve detection and treatment planning.

China’s Guillain-Barre Syndrome diagnostics market is growing due to heightened awareness and increasing healthcare accessibility. As more patients seek early diagnosis, advanced diagnostic methods such as molecular testing and imaging techniques are becoming more widely used. The diagnosis of rare GBS variants, such as Miller Fisher Syndrome (MFS), is also improving with enhanced laboratory capabilities.

Latin America GBS Diagnostics Market Trends

The Latin American Guillain-Barre Syndrome diagnostics market is expanding, particularly in Brazil, where increasing disease prevalence and improving healthcare access are driving demand. Advanced diagnostic techniques, including electromyography and nerve conduction studies, are becoming more widely available in hospitals and diagnostic laboratories.

Brazil GBS diagnostics market is experiencing significant growth due to rising awareness and better diagnostic accessibility. Healthcare improvements are increasing the availability of diagnostic solutions for severe GBS subtypes, including acute inflammatory demyelinating polyneuropathy (AIDP) and CIDP. Investments in public healthcare infrastructure are further enhancing diagnostic capabilities.

Middle East and Africa GBS Diagnostics Market Trends

The GBS diagnostics market in the MEA region is expanding as awareness campaigns and healthcare investments improve access to diagnostic solutions. Countries such as Saudi Arabia, the UAE, and South Africa are witnessing increased demand for accurate diagnostic tools, particularly in hospital settings.

Saudi Arabia’s GBS diagnostics market is growing rapidly due to healthcare reforms under the Vision 2030 initiative. Early detection programs and the adoption of advanced diagnostic tools, such as biomarker analysis and nerve conduction studies, are driving market expansion. Increased investments in healthcare infrastructure are expected to further enhance diagnostic accessibility across the country.

Key Guillain-Barre Syndrome Diagnostics Company Insights

Some major players catering to the Guillain-Barre syndrome diagnostics market are Cadwell Industries, Inc.; Natus Medical Incorporated; Nihon Kohden Corporation; Medtronic plc; Bionen Medical Devices; Deymed Diagnostic; Neurosoft; Alpine Biomed; EMS Biomedical; Rochester Electro-Medical, Inc.; among others There are various small and large manufacturers offering products, resulting in intense competition among the manufacturers.

The industry players are increasing their focus on strategic partnerships such as mergers and acquisitions, new product launches & partnerships & collaborations to get maximum revenue share in this sector.

Recent Developments

• In December 2024, Hansa Biopharma initiated enrollment for a Phase II trial investigating imlifidase as a potential treatment for Guillain-Barré Syndrome (GBS). The trial aims to evaluate the safety, tolerability, and efficacy of imlifidase when used in combination with the standard Intravenous Immunoglobulin (IVIG) treatment for GBS patients.

• In October 2023, the European Academy of Neurology and the Peripheral Nerve Society developed evidence-based guidelines for diagnosing and treating Guillain-Barré syndrome (GBS) using GRADE methodology. Key recommendations include early intravenous immunoglobulin (IVIg) or plasma exchange for patients within two to four weeks, testing for anti-GQ1b antibodies in Miller Fisher syndrome, and using the modified Erasmus GBS outcome score (mEGOS) to assess prognosis.

• In October 2023, Neurology published a study revealing that a recent COVID-19 infection increases the risk of developing Guillain-Barré syndrome (GBS) six-fold within six weeks. The study found that 12% of GBS patients had recent infections compared to only 2% of non-GBS cases. Moreover, individuals receiving the Pfizer-BioNTech mRNA vaccine had a lower GBS risk, underscoring vaccination’s protective benefits.

Guillain-Barre Syndrome Diagnostics Market Report Scope

Global Guillain-Barre Syndrome Diagnostics Market Report Segmentatio

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global GBS diagnostics market report based on test, end use, and region:

• Test Outlook (Revenue, USD Million, 2018 - 2030)

  • Lumbar Puncture

  • Nerve Conduction

  • Electromyography

  • Other

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals and Clinics

  • Diagnostic Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait